Drugs in ATC Class A10BX

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A10 - DRUGS USED IN DIABETES

Up to A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

Drugs in ATC Class: A10BX - Other blood glucose lowering drugs, excl. insulins

Tradename	Generic Name
PRANDIMET	metformin hydrochloride; repaglinide
REPAGLINIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; repaglinide
PRANDIN	repaglinide
REPAGLINIDE	repaglinide
NATEGLINIDE	nateglinide
STARLIX	nateglinide
SYMLIN	pramlintide acetate

Last updated: June 2, 2026

ATC A10BX (Other blood glucose lowering drugs excl. insulins) Market Dynamics and Patent Landscape: Which products face generic or biosimilar risk?

ATC class A10BX (“Other blood glucose lowering drugs, excluding insulins”) is dominated by incretin-based therapies and dual-target agents, with patent and exclusivity risk concentrated in molecules that already have first generic entry or are approaching the end of their regulatory data protection. The patent estate is split between (i) active pharmaceutical ingredient (API) composition-of-matter, (ii) long-acting or delivery-system patents (injectable formulations, depots, prodrugs), and (iii) method-of-use patents tied to specific patient populations, dosing schedules, and combination regimens.

A10BX market dynamics are driven by GLP-1 receptor agonist (GLP-1 RA) uptake and tolerability-led switching, while competitive intensity accelerates as payers tighten step edits and as first and second wave generics and “next-in-class” products compress net prices. Patent risk tends to be highest where Orange Book coverage is thin, where formulation patents expire earlier than API patents, and where litigation has already produced settlement or authorization to launch.

Which drugs are in ATC A10BX and how do their patent estates differ?

Featured snippet answer: A10BX spans non-insulin glucose-lowering therapies that are not classified within the main GLP-1, DPP-4, or SGLT2 sub-classes under ATC conventions used by many databases. In practice, the segment’s patent landscape clusters around incretin agents (GLP-1 RA, dual GLP-1/GIP) and related delivery systems that carry both API and formulation barriers.

Common A10BX-active ingredient groups that shape the patent map

• GLP-1 receptor agonists and dual incretin agents: typically carry long method-of-use coverage and injectable delivery-system patents (extended-release, stability, particle size, device/needle systems).
• Other non-insulin glucose-lowering agents that are not centered in insulin, metformin, sulfonylurea, thiazolidinedione, or SGLT2/ DPP-4 segments under typical ATC drilldowns often still cluster in method-of-use and formulation protection.

Why A10BX patent estates differ

• API patents often expire earlier than the latest regulatory exclusivity, but composition-of-matter coverage is usually strongest against direct “same compound” generics.
• Formulation patents can outlast API by years where long-acting depots, solubilizers, or micro-/nano-structure are patented.
• Method-of-use patents are frequently asserted against “carve-outs” (e.g., specific titration, dosing schedules, or combination indications) and can block design-around generics even after API expiry in some litigation outcomes.

What patents protect ATC A10BX products: composition of matter vs formulations vs methods of use?

Featured snippet answer: The protective layers for A10BX products are usually (1) API composition-of-matter, (2) long-acting injectable formulation and stability patents, and (3) method-of-use patents covering specific indications, dosing regimens, and combination therapies.

Composition-of-matter patents (API)

• Cover the active agent’s chemical identity and key structural features.
• Strongest against true “generic same-molecule” challenges, unless the generic parties clear patent-by-patent coverage or rely on expiration.

Formulation and delivery system patents

• Injectable stability and shelf-life (including refrigerated storage characteristics).
• Particle or depot architecture for extended-release GLP-1 RA analogs.
• Device-linked patents can also exist (pen injection mechanisms, dosing accuracy, reconstitution features for certain products).

Method-of-use patents

• Tied to: HbA1c reduction in defined populations, combination therapy with specific co-medications, renal or cardiovascular subgroup claims (where pursued in label updates), and dosing/titration schemes.
• Often asserted in litigation to limit “generic design” from using alternative instructions that could otherwise be considered non-infringing.

How many patents cover A10BX drugs and what does “Orange Book thickness” predict about launch risk?

Featured snippet answer: Launch risk rises when Orange Book coverage is sparse (few listed patents, short remaining term, or high concentration in expiring formulations rather than API). Launch risk drops when coverage is dense across API, formulation, and multiple method-of-use patents with overlapping remaining life.

Patent coverage density: practical interpretation

• High coverage density typically corresponds to multiple Orange Book-listed patents spanning different expiration dates, creating staggered barriers for Paragraph IV challengers.
• Thin coverage tends to shift risk toward regulatory exclusivity and manufacturing know-how rather than patent blocking.

What to track for each A10BX product

• Number of listed patents per NDA/BLA on the Orange Book.
• Whether key patents are:
  • API (often harder to design around),
  • formulation (harder due to stability and delivery system equivalence),
  • method-of-use (harder if label carve-out does not align with generic proposed indication).
• Expiration-date distribution: a “cliff” versus “stair-step” pattern.

When does exclusivity end for ATC A10BX drugs: patent expiration vs data exclusivity vs pediatric exclusivity?

Featured snippet answer: For A10BX molecules, exclusivity is typically layered: patent expiry (composition/formulation/method) plus FDA exclusivity protections that can extend effective market protection even after some patents expire.

Key exclusivity mechanisms impacting A10BX launch timing

• NCE exclusivity (new molecular entity) where applicable.
• 3-year new clinical investigation exclusivity.
• 5-year exclusivity tied to certain approval contexts.
• Pediatric exclusivity (six-month extension) triggered by pediatric study submissions.

Timing model used in portfolio planning

• Identify latest expiring protection among:
  1. API composition-of-matter,
  2. formulation patents listed in the Orange Book,
  3. method-of-use patents with relevant indication alignment,
  4. regulatory exclusivity end dates,
  5. any settlement-triggered stay end dates (if Paragraph IV is litigated and resolved).

Which ATC A10BX patents are usually the last to expire, and why do they matter for generics?

Featured snippet answer: The last-to-expire coverage for many A10BX therapies is frequently method-of-use and long-acting formulation patents, because they are added in label expansions, new dosing convenience updates, and post-approval reformulation efforts.

Common “last-mile” patent types

• Extended-release/injectable stability and device integration.
• Specific dosing regimens tied to label titration schedules or maximum dose instructions.
• Combination regimen coverage (particular co-therapies that align with payer and prescriber behavior).

What Paragraph IV challenges exist for A10BX drugs and what do they signal for future generic entry?

Featured snippet answer: Paragraph IV filings are the leading forward signal for generic launch pressure, but actual timing depends on whether challenges target API versus formulation/method patents and whether settlements convert potential injunction risk into fixed launch dates.

How to read Paragraph IV strategy for A10BX

• If challengers target only earliest-expiring patents, they can still face injunction risk from later-expiring formulation/method patents.
• If challengers file ANDAs without an indication carve-out that avoids method-of-use coverage, courts may enjoin until resolution.
• Settlement outcomes often convert litigation uncertainty into a predictable launch window, even when not all patents are resolved.

What patent litigation affects ATC A10BX products: settlements, stays, and injunction risk?

Featured snippet answer: The highest litigation impact for A10BX therapies comes from settlements and consent judgments that define when a generic can market. These settlements commonly include provisions that link to specific patent expiry windows and may include carve-outs on labeling and dosing instructions.

Common litigation outcomes in this segment

• Auto-stay expiration if FDA approval triggers but litigation is ongoing (depending on timing).
• Injunctions if infringement is found on key patents that remain unexpired.
• Final judgments that narrow asserted claims to specific patents and force design-around for the generic.

Portfolio implications

• Settlements reduce uncertainty for market entry but can create “quasi-exclusive” windows for the branded product well beyond earliest patent expiry.

What is the biosimilar or biogeneric risk in ATC A10BX?

Featured snippet answer: Biosimilar risk exists where A10BX includes biologic incretin products approved via protein pathways (BLA/biologic). Market entry risk then depends on biosimilarity demonstration, manufacturing comparability, and any use-label restrictions tied to method-of-use patents.

Typical biosimilar/pseudo-biosimilar drivers

• Patent estate for biologics often includes method-of-use claims more frequently than small molecules.
• Even when biosimilar approval is supported, labeling differences and patent carve-outs drive practical substitution.

Which formulation patents protect injectable A10BX drugs and how do they block design-around?

Featured snippet answer: Injectable formulation patents block design-around by protecting stability, solubilizer composition, viscosity range, particle characteristics, and device-linked dosing performance needed for therapeutic equivalence.

Design-around pressure points

• Alternative excipient compositions that still meet stability specifications can trigger infringement if claim scope is broad.
• Different particle architecture or depot structure may avoid formulation claims but can still infringe if the functional limitations are captured.
• Label titration instructions can create method-of-use infringement risk even when the molecule differs in formulation.

How does A10BX compare with other glucose-lowering ATC classes on IP strength and generic timing?

Featured snippet answer: A10BX, where incretin-based injectables dominate, generally carries stronger IP barriers than SGLT2 or DPP-4 segments due to layered formulation and method-of-use coverage plus biologic-like constraints for manufacturing equivalence.

Relative patterns

• SGLT2 inhibitors: more accessible small-molecule generics historically, with IP barriers concentrated in API and fewer formulation layers (varies by product).
• DPP-4 inhibitors: often face staggered patent cliffs but fewer device-linked issues.
• A10BX incretin injectables: fewer direct “copy” candidates due to formulation stability and device performance constraints, and frequent method-of-use expansions.

Commercial dynamics: how payer pressure and adherence affect the value of patent-protected A10BX therapies

Featured snippet answer: In A10BX, net sales sensitivity is high to adherence and switching economics, so brand value depends on real-world persistence as well as label breadth. Patent barriers thus protect not only molecule identity but also treatment patterns that drive payer and patient lock-in.

Key market forces

• Payer step edits and formulary tiers: intensify switching to preferred agents when price concessions or rebates change.
• Tolerability and dosing convenience: affect persistence and capture rates; these attributes correlate with protected delivery systems.
• Combination positioning: brands protected by method-of-use patents can defend high-value lines of therapy longer than pure API expiry would suggest.

Key takeaways

• A10BX patent risk is layered: API, long-acting formulation, and method-of-use patents govern generic feasibility more than single-date API expiry.
• Launch threats increase where Orange Book coverage is thin or where only earlier-expiring formulation patents are targeted.
• Litigation outcomes matter because settlements and labeling carve-outs can set practical launch dates even when patent validity is still contested.
• Commercial leverage remains tied to dosing convenience and persistence, which are frequently protected by formulation and device-linked patent coverage.
• Biosimilar risk is material for biologic incretin products, and method-of-use patents can still limit substitutability despite biosimilar approval.

FAQs

1. What is the fastest legal pathway for generic entry into an A10BX therapy once API patents expire?
2. Which Orange Book patent types (method-of-use vs formulation vs composition) most often trigger injunctions for A10BX products?
3. How do label carve-outs and indication changes influence infringement risk for A10BX generics?
4. Do settlements in A10BX Paragraph IV cases usually lock in fixed launch dates, and what triggers them?
5. How does device-linked IP (pens, needles, dosing mechanisms) affect the feasibility of “authorized” or generic entry for injectable A10BX drugs?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-02).